Immunomedics, Inc. (NASDAQ:IMMU) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $14.57 and last traded at $14.49, with a volume of 1658207 shares changing hands. The stock had previously closed at $13.81.
A number of research firms have issued reports on IMMU. ValuEngine lowered Immunomedics from a “hold” rating to a “sell” rating in a research report on Monday, December 4th. Zacks Investment Research raised Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Wednesday, October 4th. Jefferies Group raised their target price on Immunomedics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Finally, BidaskClub raised Immunomedics from a “hold” rating to a “buy” rating in a research report on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Immunomedics presently has an average rating of “Buy” and a consensus price target of $15.33.
The stock has a market cap of $2,099.41, a PE ratio of -6.57 and a beta of 1.51. The company has a quick ratio of 0.74, a current ratio of 0.74 and a debt-to-equity ratio of -0.29.
Hedge funds have recently made changes to their positions in the business. Amalgamated Bank boosted its stake in shares of Immunomedics by 8.1% in the second quarter. Amalgamated Bank now owns 12,911 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 966 shares in the last quarter. Stephens Inc. AR purchased a new stake in Immunomedics during the second quarter worth $115,000. Raymond James Financial Services Advisors Inc. boosted its position in Immunomedics by 11.4% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 1,473 shares in the last quarter. SG Americas Securities LLC boosted its position in Immunomedics by 99.3% during the second quarter. SG Americas Securities LLC now owns 20,719 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 10,323 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in Immunomedics by 38.8% during the first quarter. Bank of America Corp DE now owns 33,707 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 9,426 shares in the last quarter. Institutional investors own 76.28% of the company’s stock.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.